A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, and Pharmacokinetics After Multiple-dose Administration of 25 mg Aprocitentan in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Aprocitentan (Primary)
- Indications Cardiovascular disorders; Hypertension
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
- 16 Oct 2018 Status changed from recruiting to completed.
- 23 Jul 2018 Status changed from not yet recruiting to recruiting.
- 18 Jul 2018 New trial record